Loncar Investments
Fund & Investor Interest: LoncarFund: Reflections on a Recent Trip to Asia
Loncar Investments

Brad Loncar, CEO of Loncar Investments and creator of the Loncar China BioPharma Index, offers some thoughts on the progress of China biotech after a recent trip to the region.

Here are five things I saw on the trip:

1. Pricing, Pricing, Pricing

2. Hong Kong Stock Exchange’s Biotech Experiment is Gaining Steam

3. There is Literally a Frenzy to In-license Western Drugs to China

4. There is also a Frenzy for Talent that is Driving up Costs

5. Chinese Companies are Getting More Drugs into the Clinic in the United States